Essential cancer medicines: adding feasibility to the magnitude of clinical benefit value chain.

Fiche publication

Date publication

octobre 2023

Journal

ESMO open

Auteurs

Membres identifiés du Cancéropôle Est :
Dr AMARAL Teresa Maria

Tous les auteurs :
Roitberg F, Amaral T, Cherny NI, Giuliani R, Latino NJ, Galotti M, Bricalli G, Curigliano G, Pentheroudakis G, Trapani D

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37672862

Résumé

Cancer is a global public health problem, requiring efficient health system investments to deliver sustainable impact on population health. Access to medicines is a critical component of health systems, having a crucial role in delivering therapeutic benefits. Since 1977, the World Health Organization (WHO) has published a Model List of Essential Medicines (EML) that includes key health interventions for the prevention and control of conditions of public health relevance. Essential medicines are selected for inclusion in the EML based on the evidence of efficacy, safety, therapeutic value, and the potential to impact population health. With the rapid changes in the therapeutic landscape of cancer treatment with new medicine approvals, there is a critical need to select and prioritise specific cancer interventions based on their intrinsic value.